Atopic Dermatitis: Update on Skin-Directed Management: Clinical Report
Jennifer J. Schoch, Katelyn Anderson, Amie E. Jones, Megha M. Tollefson, Section on Dermatology, Teresa L. Wright, Raegan Hunt, Christine T. Lauren, Christina Boull, Deepti Gupta, Brandi Kenner‐Bell
Abstract
Atopic dermatitis affects 20% to 25% of children and has significant impact on quality of life of patients and families. Recent studies of the pathogenesis of AD highlight the interplay between a defective skin barrier, immune dysfunction, and the cutaneous microbiome. Standard of care for AD treatment includes topical corticosteroids for active disease and moisturization to repair the barrier defect. Emerging treatments include dupilumab and Janus kinase (JAK) inhibitors. Reduction of triggers and proactive treatment with topical corticosteroids and/or topical calcineurin inhibitors can reduce flares. Treatment plans should be clear and as simple as possible to maximize adherence.